DHEA hormone to treat ovarian aging
- Conditions
- Women having low ovarian reserve undergoing IVF/ICSI treatmentTherapeutic area: Body processes [G] - Reproductive physiologi cal processes [G08]
- Registration Number
- EUCTR2011-002425-21-GB
- Lead Sponsor
- niversity of Nottingham
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- Female
- Target Recruitment
- 0
1. Women aged =23 years with diminished ovarian reserve Antral follicle count of =10 or Anti-Mullerian hormone levels <5pmol/L 2. Women undergoing IVF/ICSI treatment 3. Women must have a regular spontaneous menstrual cycle of 21 – 35 days 4. Women must be willing and comply with scheduled visits, treatment plan and laboratory tests.
Are the trial subjects under 18? no
Number of subjects for this age range: 0
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 50
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range 0
1. BMI >35 Kg/M2 2. Women with a single ovary 3. Untreated hydrosalpinx/ submucous fibroid/ Endometrial polyp at the start of treatment 4. Any history of seizure disorders 5. Previous participation in this trial in an earlier treatment cycle 6. Any known endocrine disorders such as congenital adrenal hyperplasia, thyroid diseases, hyperprolactinemia 7. Known allergy to DHEA 8. Diabetic women on insulin (Insulin lower the DHEA levels and might lower the effectiveness of DHEA supplements)
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method